A Comprehensive Monograph on Sulpiride: Pharmacology, Clinical Utility, and Safety Profile

Executive Summary

Sulpiride is a substituted benzamide derivative with a unique pharmacological profile that positions it distinctly within the class of antipsychotic agents. First described in the 1960s, it functions primarily as a selective antagonist of dopamine D2 and D3 receptors. Its most notable characteristic is a dose-dependent bimodal mechanism of action: at low doses, it exhibits a disinhibitory, antidepressant effect by blocking presynaptic autoreceptors, thereby enhancing dopaminergic neurotransmission; at higher doses, it exerts a conventional postsynaptic blockade, producing antipsychotic effects. This dual action underpins its wide therapeutic applications, which include the treatment of acute and chronic schizophrenia, depressive and anxiety disorders, vertigo, and certain functional gastrointestinal conditions.

Pharmacokinetically, Sulpiride is characterized by poor and variable oral bioavailability, which is further reduced by food intake. It undergoes minimal metabolism and is eliminated almost entirely unchanged via renal excretion, a factor that necessitates careful dose adjustments in patients with renal impairment and in the elderly. Its safety profile is marked by a significant risk of dopamine-mediated adverse effects, including extrapyramidal symptoms (EPS) and hyperprolactinemia, with a frequency and severity that can be comparable to older, "typical" antipsychotics. However, due to its high receptor selectivity, it is associated with a lower incidence of anticholinergic, antihistaminic, and alpha-adrenergic side effects like sedation and orthostatic hypotension.

The global regulatory landscape for Sulpiride is notably fragmented. It is not approved by major centralized agencies such as the U.S. Food and Drug Administration (FDA), Health Canada, or the European Medicines Agency (EMA) for pan-European marketing. Nevertheless, it holds marketing authorization in numerous individual European, Asian, and South American countries, reflecting a therapeutic legacy that predates modern, harmonized regulatory standards. This comprehensive monograph synthesizes the available evidence on Sulpiride's chemical properties, complex pharmacology, clinical applications, and safety profile to provide a definitive reference for clinicians and researchers.

Section 1: Drug Identification and Physicochemical Profile

This section establishes the fundamental identity of Sulpiride, providing the necessary chemical and physical data that form the basis for its pharmacological properties.

1.1. Nomenclature and Identifiers

Sulpiride is known by a variety of names and is cataloged across numerous chemical and pharmacological databases. Establishing its precise identity is the first step in a comprehensive analysis.

• Generic Name: Sulpiride.[1]
• Systematic (IUPAC) Name: N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide.[2]
• DrugBank ID: DB00391.[1]
• CAS Number: 15676-16-1.[1]
• Synonyms: The compound is referenced by numerous synonyms, including its racemic designation, (±)-sulpiride, and various chemical descriptors such as 5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide, N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide, Sulpirid, and Sulpirida.[1]
• Brand Names: Sulpiride was originally developed by Delagrange in France in 1969 and marketed under the brand name Dogmatil.[7] It is available globally under a wide array of trade names, including but not limited to Dolmatil, Eglonyl, Sulpor, Meresa, Miradol, Guastil, Abilit, Aiglonyl, Coolspan, Dobren, Espiride, and Modal.[5]

1.2. Chemical Structure and Stereochemistry

The molecular structure and stereoisomeric properties of Sulpiride are fundamental to its interaction with biological targets.

• Chemical Formula: $C_{15}H_{23}N_{3}O_{4}S$.[1]
• Molecular Weight: The average molecular weight is 341.43 g/mol (or 341.426 g/mol), with a monoisotopic mass of 341.140926929 g/mol.[1]
• Structural Identifiers: For unambiguous identification in computational and chemical databases, the following identifiers are used:
• SMILES: CCN1CCCC1CNC(=O)c2cc(ccc2OC)S(=O)(=O)N.[13]
• InChI: InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21).[13]
• InChIKey: BGRJTUBHPOOWDU-UHFFFAOYSA-N.[8]
• Stereochemistry: Sulpiride is a chiral molecule and is commercially available as a racemic mixture of its two enantiomers: (S)-(-)-sulpiride and (R)-(+)-sulpiride.[6] The primary pharmacological activity, particularly the D2 receptor antagonism, resides in the (S)-enantiomer, also known as levosulpiride.[12] Levosulpiride is itself marketed as a separate therapeutic agent in some countries for indications including psychotic disorders, depression, and gastroparesis.[14]

The existence of levosulpiride as a distinct clinical entity has significant implications. It demonstrates that the therapeutic effects of racemic Sulpiride are driven predominantly by one isomer. The (R)-enantiomer may be pharmacologically inert or could contribute differently to the drug's overall profile, potentially including its adverse effects. This raises the possibility that the therapeutic index of Sulpiride could be optimized by using the pure, active (S)-enantiomer. Clinical studies conducted with the racemic mixture may therefore not fully represent the most refined balance of efficacy and tolerability achievable with this chemical scaffold.

1.3. Physical and Chemical Properties

Sulpiride's physical properties influence its formulation, stability, and pharmacokinetic behavior.

• Appearance: It is a white to beige crystalline solid or powder.[4]
• Melting Point: The melting point is in the range of 178-180°C.[7]
• Solubility: Sulpiride is classified as a Biopharmaceutical Classification System (BCS) class IV drug, indicating both poor aqueous solubility and limited intestinal permeability.[15] It is slightly soluble in water ($<0.21$ g/L at 25°C) and soluble in ethanol, 0.1 M HCl ($>40$ mg/mL), and DMSO (up to 100 mM).[4] Its solubility can be enhanced in cyclodextrin solutions; for example, 8.0 mg/mL in 45% (w/v) aqueous 2-hydroxypropyl-β-cyclodextrin.[4]
• pKa: The molecule has two ionization constants, with pKa values of 9.00 and 10.19 at 25°C.[8]
• Storage and Stability: It is recommended to be stored under refrigeration at 2-8°C.[4] Solutions may be stored for several days at 4°C.[4]

Table 1: Key Identification and Physicochemical Properties of Sulpiride
Property	Value / Identifier
Generic Name	Sulpiride
DrugBank ID	DB00391
CAS Number	15676-16-1
EC Number	239-753-7
UNII	7MNE9M8287
Chemical Formula	$C_{15}H_{23}N_{3}O_{4}S$
Average Molecular Weight	341.43 g/mol
Appearance	White to beige solid powder
Melting Point	178-180°C
pKa	9.00, 10.19
Water Solubility	Slightly soluble ($<0.21$ g/L at 25°C)
Ethanol Solubility	Soluble
0.1 M HCl Solubility	Soluble ($>40$ mg/mL)
Recommended Storage	2-8°C

Section 2: Pharmacology and Mechanism of Action

This section dissects the complex pharmacology of Sulpiride, explaining how its molecular interactions translate into its diverse clinical effects.

2.1. Primary Mechanism: Selective Dopamine Receptor Antagonism

Sulpiride is a substituted benzamide derivative whose primary mechanism of action is the selective antagonism of dopamine receptors.[1] It exhibits a high affinity for the D2 and D3 dopamine receptor subtypes, which are key components of the mesolimbic and mesocortical pathways implicated in psychosis and mood regulation.[1] Its affinity for the D4 receptor subtype is considerably lower.[6] The blockade of postsynaptic D2 receptors in the mesolimbic system is believed to be the principal action responsible for its antipsychotic effects, leading to a reduction in the "positive" symptoms of schizophrenia, such as hallucinations and delusions.[17]

2.2. Dose-Dependent Bimodal Action

A defining and unique characteristic of Sulpiride's pharmacology is its bimodal, dose-dependent effect on the dopaminergic system.[3] This dual action allows it to be used across a spectrum of psychiatric conditions that are theoretically associated with opposing states of dopamine activity.

• Low Doses (approximately 50-200 mg/day): At lower concentrations, Sulpiride acts preferentially on presynaptic D2 autoreceptors.[17] These autoreceptors function as a negative feedback mechanism, sensing synaptic dopamine levels and inhibiting further dopamine synthesis and release when activated. By blocking these autoreceptors, Sulpiride removes this inhibitory brake, resulting in an increase in dopamine synthesis and release into the synapse. This facilitation of dopaminergic neurotransmission produces a disinhibitory, activating, and antidepressant effect.[3] This mechanism underpins its efficacy in treating depressive disorders and the negative symptoms of schizophrenia, which are hypothesized to involve hypodopaminergic states in certain brain regions like the prefrontal cortex.
• High Doses (approximately 600-1600 mg/day): As the dose is increased, Sulpiride's concentration in the brain becomes sufficient to overcome its presynaptic preference and significantly occupy postsynaptic D2 receptors.[3] This postsynaptic antagonism blocks the action of dopamine, leading to a reduction in dopaminergic hyperactivity in pathways like the mesolimbic system. This is the conventional antipsychotic mechanism responsible for treating the positive symptoms of psychosis.[17]

This elegant bimodal mechanism is the central pharmacological principle that unifies Sulpiride's diverse clinical applications. It explains how a single molecule can be prescribed for seemingly opposite conditions: a low dose is used to enhance dopaminergic tone to treat depression, while a high dose is used to dampen it to treat psychosis.

2.3. Receptor Binding Profile and Atypicality

Sulpiride's classification as an "atypical" antipsychotic is a subject of nuance and debate.[3] Its atypicality is primarily derived from its high receptor selectivity rather than the broader receptor binding profile seen in many second-generation agents like olanzapine or risperidone.

Sulpiride demonstrates minimal affinity for serotonin (5-HT2A, though some antagonism is noted at doses >600 mg/day), alpha-adrenergic, histamine H1, or muscarinic cholinergic receptors.[3] This selectivity is clinically significant, as it accounts for the relative absence of many common side effects associated with other antipsychotics. For instance, the lack of H1 antagonism means less sedation and weight gain, and the lack of muscarinic antagonism means fewer anticholinergic effects (e.g., dry mouth, constipation, blurred vision).[17]

However, the "atypical" label can be misleading if it is interpreted as implying a low risk of all classic antipsychotic side effects. Sulpiride's potent D2 blockade in pathways like the nigrostriatal and tuberoinfundibular tracts leads to a significant risk of extrapyramidal symptoms (EPS) and hyperprolactinemia, respectively.[3] Studies have shown that its risk of inducing these dopamine-mediated side effects can be as high as that of the "typical" antipsychotic haloperidol.[20] Therefore, its atypicality lies in its "cleaner" profile regarding non-dopaminergic receptors, not necessarily in a reduced liability for D2-blockade-related adverse events. This distinction is critical for clinicians to avoid a false sense of security regarding the risk of movement disorders and endocrine dysfunction.

2.4. Activity at Other Biological Targets

Beyond its primary action on dopamine receptors, Sulpiride has been found to interact with several other biological targets, although the clinical significance of these interactions is less well-established.

• Carbonic Anhydrases: In vitro studies have identified Sulpiride as an inhibitor of several human carbonic anhydrase (CA) isoforms, including CA1, CA2, CA3, CA7, and CA12. It shows a particularly high affinity for CA12, with a pKi of 8.4 (Ki of $3.9 \times 10^{-9}$ M).[6] Carbonic anhydrases are involved in a wide range of physiological processes, but the contribution of this inhibitory activity to Sulpiride's therapeutic or adverse effect profile is not currently understood.
• Cholinesterase: It is listed as a cholinesterase inhibitor, another non-dopaminergic action that could theoretically influence cognitive or autonomic function.[21]
• Sigma Receptors: Sulpiride possesses some affinity for sigma receptors. These receptors are involved in neuroprotection and the modulation of various neurotransmitter systems, but their role in the pharmacodynamics of Sulpiride remains speculative.[17]
• Gamma-Hydroxybutyrate (GHB) Receptor: Like other benzamide neuroleptics, Sulpiride has been shown to activate the endogenous GHB receptor in vivo at therapeutic concentrations.[3]

Table 2: Receptor and Enzyme Binding Affinities of Sulpiride
Target	Species	Action	Affinity (pKi)	Affinity (Ki)
D2 Dopamine Receptor	Human	Antagonist	7.2 – 7.9	$1.2 \times 10^{-8}$ – $6 \times 10^{-8}$ M
D3 Dopamine Receptor	Human	Antagonist	6.8 – 7.8	$1.4 \times 10^{-8}$ – $1.42 \times 10^{-7}$ M
D4 Dopamine Receptor	Human	Antagonist	-	$2.1 \times 10^{-6}$ M
Carbonic Anhydrase 12	Human	Inhibitor	8.4	$3.9 \times 10^{-9}$ M
Carbonic Anhydrase 1	Human	Inhibitor	5.9	$1.2 \times 10^{-6}$ M
Carbonic Anhydrase 7	Human	Inhibitor	5.4	$3.63 \times 10^{-6}$ M

Data compiled from source.[6]

Section 3: Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

This section details the disposition of Sulpiride within the human body, outlining the key pharmacokinetic parameters that govern its clinical use, dosing schedules, and potential for adverse effects in specific populations.

3.1. Absorption and Bioavailability

The absorption of Sulpiride following oral administration is a significant clinical challenge due to its poor and variable nature.

• Bioavailability: The absolute oral bioavailability is low, with estimates ranging from 25% to 40%.[3] A more precise study measured it at $27 \pm 9\%$.[1] This poor absorption is a primary contributor to the high doses required for antipsychotic effects and can lead to significant inter-individual variability in plasma concentrations and clinical response.
• Pharmacokinetic Parameters: Following a single oral dose of 100-108 mg, the maximum plasma concentration ($C_{max}$) ranges from 232 to 403 ng/mL, which is reached at a relatively late time to maximum concentration ($T_{max}$) of 8.3 hours.[1] The area under the plasma concentration-time curve (AUC) for a 100 mg oral dose was measured at $1156 \pm 522$ hng/mL, compared to $3981 \pm 813$ hng/mL for an equivalent intravenous dose, further illustrating its limited oral absorption.[1]
• Food and Drug Effects on Absorption: The bioavailability of Sulpiride is significantly influenced by co-administration with food or certain medications. Both food intake and the size of the meal have been shown to decrease its gastrointestinal absorption by approximately 30%.[22] Concurrently administered antacids or sucralfate can also reduce absorption, likely through chelation or by altering gastric pH.[24]

3.2. Distribution

Once absorbed into the systemic circulation, Sulpiride distributes throughout the body.

• Protein Binding: Sulpiride exhibits relatively low plasma protein binding, with approximately 40% bound, primarily to albumin.[1] This low level of binding means a larger fraction of the drug is free (unbound) and pharmacologically active, but it also means that its distribution is less likely to be affected by conditions that alter plasma protein levels or by displacement interactions with other highly protein-bound drugs.
• Volume of Distribution: The average volume of distribution ($V_d$) is reported as $2.72 \pm 0.66$ L/kg, indicating moderate distribution into tissues beyond the plasma volume.[1] Other estimates place the range at 1.2-1.7 L/kg.[8]
• Blood-Brain Barrier Penetration: A critical aspect of its distribution is its poor penetration of the blood-brain barrier. This is attributed to its low lipid solubility and its nature as a substrate for efflux transporters like P-glycoprotein.[7] This property may contribute to its relatively wider therapeutic window, as higher peripheral concentrations are required to achieve therapeutic concentrations in the central nervous system.

3.3. Metabolism

Sulpiride's metabolic profile is remarkably simple and is a key feature distinguishing it from many other psychotropic medications.

• Minimal Metabolism: The drug undergoes very little to no metabolism in the body. Approximately 95% of an administered dose is recovered as the unchanged parent compound.[1] This lack of significant biotransformation means that Sulpiride is not a substrate for, nor does it inhibit or induce, the Cytochrome P450 (CYP) enzyme system.[3] Consequently, it has a very low potential for metabolic drug-drug interactions, a significant advantage in polypharmacy situations common in psychiatric patients.

3.4. Elimination and Excretion

The elimination of Sulpiride is almost entirely dependent on renal function.

• Route of Elimination: The primary route of elimination is renal excretion of the unchanged drug.[15]
• Urinary Excretion: Following an intravenous dose, $70 \pm 9\%$ is recovered in the urine within 36 hours. After an oral dose, the urinary recovery is $27 \pm 9\%$, a figure that directly reflects its oral bioavailability.[1]
• Half-life: The elimination half-life ($t_{1/2}$) is reported to be in the range of 6 to 9 hours.[1] This relatively short half-life necessitates twice-daily dosing to maintain steady-state plasma concentrations.[1]
• Clearance: The total systemic clearance is approximately $415 \pm 84$ mL/min, with renal clearance accounting for the majority of this at $310 \pm 91$ mL/min.[1]

The combination of these pharmacokinetic properties—poor absorption, lack of metabolism, and near-total reliance on renal excretion—creates a high-risk profile in certain patient populations. In elderly patients, the natural age-related decline in glomerular filtration rate can lead to drug accumulation. Similarly, in any patient with pre-existing renal impairment, the clearance of Sulpiride will be significantly reduced. This accumulation dramatically increases the risk of dose-dependent adverse effects, such as EPS, NMS, and cardiac arrhythmias. This direct causal chain—from its elimination pathway to heightened risk in vulnerable groups—makes vigilant monitoring and proactive dose reduction essential clinical practices.

Table 3: Summary of Pharmacokinetic Parameters for Sulpiride
Parameter	Value
Oral Bioavailability	$27 \pm 9\%$ (range 25-40%)
$T_{max}$ (oral)	8.3 hours
Plasma Protein Binding	~40%
Volume of Distribution ($V_d$)	$2.72 \pm 0.66$ L/kg
Metabolism	Minimal (~5% of dose)
Primary Elimination Route	Renal excretion (unchanged drug)
Elimination Half-life ($t_{1/2}$)	6-9 hours
Total Systemic Clearance	$415 \pm 84$ mL/min

Section 4: Clinical Efficacy and Therapeutic Indications

This section reviews the established and investigational therapeutic uses of Sulpiride, contextualized by the available clinical evidence. Its unique bimodal pharmacology allows for its application in a diverse range of conditions.

4.1. Schizophrenia

The primary indication for Sulpiride is the management of acute and chronic schizophrenia.[1] Its efficacy profile appears to be dependent on the dose administered and the specific symptom cluster being targeted.

• Symptom Specificity: A notable feature reported in clinical studies is its differential effect on the symptoms of schizophrenia. At lower to moderate doses (up to 800 mg/day), Sulpiride is reported to be more effective in treating negative symptoms, such as apathy, anergia, flattened affect, and social withdrawal.[1] At higher doses (above 800 mg/day), its efficacy extends to cover positive symptoms, including hallucinations, delusions, and formal thought disorder, while retaining its effect on negative symptoms.[1] This aligns perfectly with its dose-dependent pharmacology, where the activating, pro-dopaminergic effect at low doses targets negative symptoms, and the postsynaptic blockade at high doses targets positive symptoms.
• Augmentation Therapy: Sulpiride has been investigated as an adjunctive therapy for patients with treatment-resistant schizophrenia who have shown only a partial response to clozapine. A Cochrane review analyzing four small, short-term trials concluded that the combination of sulpiride plus clozapine is probably more effective than clozapine monotherapy in achieving a clinical improvement.[27] However, the authors stressed that this evidence is of low quality and at considerable risk of bias, highlighting a critical need for larger, more robust clinical trials to validate this practice.[27]

4.2. Depressive and Anxiety Disorders

Leveraging its low-dose disinhibitory mechanism, Sulpiride is also used in the treatment of various mood and anxiety disorders.

• Indications: It is indicated for the treatment of depression, dysthymia (persistent depressive disorder), and some anxiety disorders, including panic disorder.[3] In Japan, it is officially approved for both schizophrenia and major depressive disorder.[3]
• Mechanism and Efficacy: Its efficacy in these conditions is attributed to its ability to enhance dopaminergic neurotransmission at low doses, which provides a stimulating and antidepressant effect.[17] Some evidence, although of low quality, suggests that Sulpiride may accelerate the therapeutic response when used as an adjunct to standard antidepressants in patients with major depressive disorder.[3]

4.3. Gastroenterological and Other Indications

Sulpiride's effects are not confined to the central nervous system, leading to its use in several non-psychiatric conditions.

• Gastrointestinal Use: It is employed as an adjunctive treatment for duodenal ulcers and other functional gastrointestinal disorders, such as irritable bowel syndrome.[7] This effect is likely mediated by its antagonism of dopamine receptors in the gastrointestinal tract, where dopamine modulates motility and secretion.
• Vertigo: In some countries, Sulpiride is an indicated treatment for vertigo, suggesting an effect on the vestibular system or its central connections.[3]
• Behavioral Disorders: It is used for the management of behavioral disturbances in both adults and children over the age of six, particularly when symptoms of agitation, aggression, or self-harm are prominent.[30]
• Galactogogue (Off-label Use): Due to its potent prolactin-elevating effect, Sulpiride has been used off-label as a galactogogue to increase milk production in lactating mothers. However, its clinical value for this purpose is considered questionable, and its use is complicated by its significant excretion into breast milk, posing a potential risk to the nursing infant.[32]

The use of Sulpiride for common conditions like peptic ulcer disease and GERD, particularly by non-psychiatrists, raises a significant public health consideration. This practice exposes a large patient population, who may not receive the same level of monitoring as psychiatric patients, to the risks of serious and potentially irreversible neurological adverse effects, such as drug-induced parkinsonism and tardive dyskinesia. A large, population-based study confirmed a significantly increased risk of parkinsonism in patients prescribed Sulpiride for these gastrointestinal indications.[33] This highlights a potential gap in clinical awareness and underscores the importance of cross-specialty education on the risks associated with centrally-acting medications used for peripheral indications.

4.4. Analysis of Clinical Trial Evidence

The clinical evidence base for Sulpiride reflects its long history, with early trials dating back to the years following its first appearance in the literature in 1967.[1]

• Historical Trials: Early double-blind, controlled trials compared Sulpiride to first-generation antipsychotics like trifluoperazine and chlorpromazine, establishing that it possessed comparable neuroleptic properties.[34]
• Modern Clinical Development: More recent clinical trial activity has been limited. Records show that Phase 3 trials investigating its use for depression, schizophrenia, dementia, and anxiety disorders have been terminated for unspecified reasons.[29] However, Phase 4 post-marketing studies for schizoaffective disorders and schizophrenia spectrum disorders have been completed, suggesting ongoing evaluation of its use in approved indications.[35]
• Combination Therapy Studies: A notable 6-week, double-blind study (NCT01615185) was designed to compare the efficacy and safety of high-dose amisulpride (a related benzamide) monotherapy versus a combination of lower-dose amisulpride plus sulpiride in patients with acute schizophrenia.[36] This reflects clinical interest in its use as part of combination strategies.
• Evidence Quality: A recurring theme in systematic reviews is the low quality and high risk of bias in the existing trial data, particularly for its use as an augmentation agent.[27] This lack of a robust, modern evidence base is a major limitation and likely a key factor in its fragmented regulatory approval status globally.

Section 5: Safety and Tolerability Profile

This section provides a comprehensive overview of Sulpiride's adverse effects, from common side effects to life-threatening risks, and outlines necessary precautions and contraindications for its safe clinical use.

5.1. Common Adverse Drug Reactions (ADRs)

The most frequently encountered adverse effects of Sulpiride are direct extensions of its pharmacological action on dopamine pathways.

• Neurological/Central Nervous System: Drowsiness and sedation are common, although often milder than with less selective antipsychotics. Conversely, insomnia, restlessness (akathisia), agitation, dizziness, and headache can also occur.[3]
• Endocrine System: Hyperprolactinemia is a very common and predictable consequence of D2 receptor blockade in the tuberoinfundibular pathway.[26] Clinically, this manifests as galactorrhea (inappropriate milk production), amenorrhea or other menstrual irregularities in women, gynecomastia (breast enlargement) in men, and decreased libido or sexual dysfunction in both sexes.[3]
• Gastrointestinal System: Anticholinergic effects such as dry mouth and constipation can occur, though they are generally less frequent than with tricyclic antidepressants or other antipsychotics.[3] Nausea, vomiting, and increased salivation have also been reported.[3]
• Metabolic Effects: Increased appetite and subsequent weight gain are known side effects.[11]
• Dermatological Reactions: Maculopapular rash is a commonly reported skin reaction.[26] Photosensitivity, where the skin becomes more sensitive to sunlight, is also a risk.[3]

5.2. Serious and High-Risk Adverse Events

While often well-tolerated, Sulpiride carries a risk of severe and potentially life-threatening adverse events that require vigilant monitoring.

• Extrapyramidal Symptoms (EPS): This is a significant risk, particularly at higher, antipsychotic doses. EPS encompasses a range of movement disorders including acute dystonia (painful muscle spasms), drug-induced parkinsonism (tremor, rigidity, bradykinesia), and akathisia (a severe sense of inner restlessness).[1] A large observational study found a strong association between Sulpiride initiation and subsequent treatment for EPS (adjusted Sequence Ratio of 1.73).[20] A nationwide population study also confirmed a nearly three-fold increased risk of developing parkinsonism in patients taking Sulpiride.[33]
• Tardive Dyskinesia (TD): With chronic use, there is a risk of developing tardive dyskinesia, which consists of involuntary, repetitive movements (often of the face, tongue, and limbs). This condition can be irreversible even after the drug is discontinued.[24]
• Neuroleptic Malignant Syndrome (NMS): This is a rare but medical emergency characterized by hyperthermia, severe muscle rigidity ("lead-pipe" rigidity), autonomic dysfunction (tachycardia, labile blood pressure), and altered mental status. It is a known risk with all D2 receptor antagonists, including Sulpiride.[1]
• Cardiovascular Effects: Sulpiride can prolong the QTc interval on an electrocardiogram (ECG). This increases the risk of serious ventricular arrhythmias, most notably Torsades de Pointes (TdP), which can be fatal.[1] Hypotension, particularly postural hypotension, and palpitations are also potential risks.[1]
• Other Rare but Serious Events: Sulpiride may lower the seizure threshold and should be used with caution in patients with epilepsy.[26] Rare cases of cholestatic jaundice, elevated liver enzymes, blood dyscrasias (including leukopenia, neutropenia, and agranulocytosis), and catatonic-like states have been reported.[3]

Table 4: Summary of Adverse Drug Reactions by Frequency and System Organ Class
System Organ Class	Frequency	Adverse Reaction
Endocrine Disorders	Common (≥1/100 to <1/10)	Hyperprolactinemia (leading to galactorrhea, amenorrhea, gynecomastia, sexual dysfunction)
Nervous System Disorders	Common	Sedation/drowsiness, insomnia, akathisia, extrapyramidal symptoms (parkinsonism, dystonia), dizziness, headache
	Rare (≥1/10,000 to <1/1,000)	Tardive dyskinesia, Neuroleptic Malignant Syndrome (NMS)
	Not Known	Convulsions, catatonia
Cardiac Disorders	Rare	Ventricular arrhythmias (e.g., Torsades de Pointes), QTc prolongation
	Not Known	Palpitations, hypotension
Gastrointestinal Disorders	Common	Constipation, dry mouth, nausea, increased salivation
Hepatobiliary Disorders	Common	Increased liver enzymes
	Rare	Cholestatic jaundice
Skin and Subcutaneous Tissue Disorders	Common	Maculopapular rash
	Rare	Photosensitivity reactions
Blood and Lymphatic System Disorders	Not Known	Leukopenia, neutropenia, agranulocytosis

Frequencies adapted from MedDRA conventions as cited in source.[26]

5.3. Contraindications and Precautions

Safe prescribing of Sulpiride requires adherence to specific contraindications and careful consideration in certain patient populations.

• Absolute Contraindications: Sulpiride should not be used in patients with:
• Known hypersensitivity to Sulpiride or other benzamides.[3]
• Pheochromocytoma, due to the risk of hypertensive crisis.[9]
• Known or suspected prolactin-dependent tumors, such as pituitary prolactinomas or breast cancer.[3]
• Acute porphyria.[3]
• Severe CNS depression, comatose state, or acute intoxication with other CNS depressants (e.g., alcohol, opiates).[3]
• Bone-marrow suppression.[3]
• Concomitant use of levodopa or other dopamine agonists due to mutual antagonism.[3]
• Precautions and Warnings: Special caution is warranted in the following populations:
• Elderly Patients: More susceptible to postural hypotension, sedation, and EPS.[26]
• Renal Impairment: Dose reduction is mandatory due to reliance on renal clearance.[26]
• Cardiovascular Disease: Risk of hypotension and arrhythmias.[30]
• Epilepsy: May lower the seizure threshold; anticonvulsant therapy should be optimized and maintained.[26]
• Parkinson's Disease: May worsen motor symptoms.[30]
• History of Glaucoma or Prostatic Hyperplasia: Due to mild anticholinergic effects.[26]

5.4. Overdose Management

Acute overdose with Sulpiride is rarely fatal but can cause significant morbidity. The clinical presentation is dose-dependent.[31]

• Symptoms: Doses of 1-3 g may cause restlessness and CNS depression. Doses of 3-7 g can lead to agitation, confusion, and prominent extrapyramidal syndromes. Doses exceeding 7 g are associated with severe hypotension and coma, which can last up to four days.[1] Other potential signs include sinus tachycardia, arrhythmias, and dystonic crises (e.g., torticollis, tongue protrusion).[1]
• Treatment: Management is primarily symptomatic and supportive. There is no specific antidote. Treatment may include gastrointestinal decontamination if appropriate, cardiovascular monitoring (especially for QTc prolongation), and respiratory support. Severe extrapyramidal reactions may respond to anticholinergic agents like biperiden or benztropine.[3]

Section 6: Clinically Significant Interactions

This section details the interactions of Sulpiride with other drugs, food, and alcohol, which can alter its efficacy and safety profile.

6.1. Pharmacodynamic Interactions

These interactions occur at the level of the drug's target receptors or physiological systems and are the most clinically significant for Sulpiride.

• CNS Depressants: The sedative effects of Sulpiride are additive with other CNS depressants. Co-administration with benzodiazepines, opioids, barbiturates, hypnotics, or alcohol can lead to excessive drowsiness, cognitive impairment, and respiratory depression.[1]
• Dopaminergic Agents: There is a mutual antagonism between Sulpiride and dopamine agonists (e.g., levodopa, bromocriptine, ropinirole, amantadine). Sulpiride will block the therapeutic effects of these agents used for Parkinson's disease, and vice versa. This combination is generally contraindicated.[1] Similarly, Sulpiride can decrease the stimulatory effects of agents like amphetamine.[1]
• QTc Prolonging Drugs: The risk of life-threatening ventricular arrhythmias, including Torsades de Pointes, is significantly increased when Sulpiride is combined with other medications known to prolong the QTc interval. This is a critical interaction to monitor. Such drugs include:
• Antiarrhythmics: Class IA (e.g., procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol).[7]
• Other Antipsychotics: Pimozide, haloperidol, droperidol, thioridazine.[7]
• Antidepressants: Tricyclic antidepressants (e.g., amitriptyline) and some SSRIs.[7]
• Antimicrobials: Macrolide antibiotics (e.g., erythromycin), fluoroquinolones (e.g., moxifloxacin), and antimalarials (e.g., amodiaquine).[1]
• Other Agents: Methadone, arsenic trioxide, pentamidine.[7]
• Antihypertensive Agents: Sulpiride can potentiate the effects of antihypertensive drugs, increasing the risk of hypotension and postural hypotension. Careful blood pressure monitoring is required.[9]
• Lithium: The combination of lithium and Sulpiride has been associated with an increased risk of extrapyramidal side effects and, possibly, neurotoxicity.[7]

6.2. Pharmacokinetic Interactions

Due to its minimal metabolism, Sulpiride is less prone to pharmacokinetic interactions than many other drugs, but interactions affecting its absorption and transport are relevant.

• CYP450 Enzymes: As Sulpiride is not significantly metabolized by and does not inhibit or induce the major CYP450 enzymes, it is not expected to have clinically significant interactions with drugs that are substrates, inhibitors, or inducers of this system.[3]
• Absorption Interactions: The absorption of Sulpiride can be significantly reduced by concurrently administered substances that alter the gastric environment. Antacids containing aluminum or magnesium, as well as sucralfate, can decrease its bioavailability and should be administered at least two hours apart from Sulpiride.[1]
• Transporter-Mediated Interactions: Sulpiride is a substrate for several important drug transporters, including Organic Cation Transporter 1 (OCT1/SLC22A1), OCT2 (SLC22A2), Multidrug and Toxin Extrusion Protein 1 (MATE1), and the efflux pump P-glycoprotein (P-gp/ABCB1).[15] While specific clinical data are limited in the provided materials, this creates a theoretical potential for interactions. For example, potent inhibitors of these transporters could increase Sulpiride concentrations, while inducers could decrease them.

6.3. Food and Alcohol Interactions

• Food: There is conflicting advice regarding administration with food. Rigorous pharmacokinetic studies demonstrate that food intake, and particularly the size of the meal, significantly decreases the gastrointestinal absorption of Sulpiride by approximately 30%.[22] This is a large and clinically relevant effect that can lead to lower plasma concentrations and potentially reduced efficacy. However, some patient-facing materials suggest it may be taken with or without food, likely as a practical measure to mitigate potential gastrointestinal upset.[37] For optimal and consistent therapeutic effect, the evidence supports administration on an empty stomach. If this causes gastric distress, it is crucial to advise the patient to take it consistently with food to avoid wide fluctuations in bioavailability.
• Alcohol: Concomitant use of alcohol is strongly discouraged. Alcohol is a CNS depressant and will potentiate the sedative and drowsy effects of Sulpiride, leading to an increased risk of accidents and impairment of cognitive and motor functions.[9]

Table 5: Clinically Significant Drug-Drug Interactions
Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence / Recommendation
Levodopa, Dopamine Agonists	Pharmacodynamic (Mutual Antagonism)	Decreased efficacy of both drugs. Combination is contraindicated.
Other CNS Depressants (Alcohol, Opioids, Benzodiazepines)	Pharmacodynamic (Additive Sedation)	Increased risk of sedation, cognitive impairment, and respiratory depression. Avoid or use with extreme caution.
QTc Prolonging Agents (e.g., Amiodarone, Moxifloxacin, Pimozide)	Pharmacodynamic (Additive QTc Prolongation)	Increased risk of life-threatening ventricular arrhythmias (Torsades de Pointes). Avoid combination where possible; requires ECG monitoring.
Antihypertensive Drugs	Pharmacodynamic (Enhanced Hypotensive Effect)	Increased risk of hypotension and orthostasis. Monitor blood pressure closely.
Lithium	Pharmacodynamic (Synergistic Toxicity)	Increased risk of extrapyramidal symptoms and neurotoxicity. Use with caution and monitor for neurological signs.
Antacids, Sucralfate	Pharmacokinetic (Reduced Absorption)	Decreased bioavailability of Sulpiride. Administer at least 2 hours apart.

Section 7: Dosage, Administration, and Formulations

This section outlines the practical aspects of prescribing Sulpiride, including available forms, recommended dosages for various indications, and necessary adjustments for specific patient populations.

7.1. Available Formulations and Strengths

Sulpiride is available in several oral formulations to accommodate different patient needs and dosing requirements.

• Forms: It is most commonly prepared as oral tablets and hard capsules.[30] An oral solution is also available, which may be beneficial for patients with difficulty swallowing or for fine-tuning dosages.[38]
• Strengths: Commercially available strengths typically include 25 mg, 50 mg, and 200 mg capsules or tablets.[31] An oral solution with a concentration of 200 mg/5 mL is also marketed.[38]

7.2. Dosing Recommendations by Indication

The dosage of Sulpiride varies dramatically depending on the therapeutic target, a direct reflection of its bimodal pharmacology.

• Schizophrenia:
• Predominantly Negative Symptoms: The initial recommended dose is 200-400 mg twice daily. The maximum dose for this indication is typically 800 mg per day.[26]
• Predominantly Positive Symptoms: Higher doses are required. Treatment is usually initiated at 400 mg twice daily and can be titrated upwards if necessary. The maximum recommended dose can be as high as 1200 mg twice daily (2400 mg/day) in severe cases.[26]
• Mixed Positive and Negative Symptoms: A dose range of 400-600 mg twice daily is often effective.[31]
• Depression and Anxiety Disorders: Lower doses that leverage the presynaptic disinhibitory effect are used.
• The typical daily dose ranges from 50 mg to 150 mg per day, which can be increased up to 300 mg per day in divided doses for milder psychiatric conditions.[9]
• Gastroenterological and Vertigo Indications:
• For use as an adjunct in duodenal ulceration or for vertigo, the recommended daily dose is 150 mg to 300 mg, administered in divided doses.[30]

7.3. Dose Adjustments in Special Populations

Careful dose adjustments are critical to ensure safety in vulnerable patient populations.

• Elderly Patients: Due to increased sensitivity to adverse effects (e.g., postural hypotension, sedation, EPS) and potential for reduced renal clearance, treatment should be initiated at a lower dose. A starting dose of 50-100 mg twice daily is recommended, with slow and careful titration based on clinical response and tolerability.[26]
• Pediatric Population: For behavioral disorders in children over the age of 6, a weight-based dose of 3-5 mg/kg/day is recommended.[30] Some guidelines do not indicate its use in children under 14 years of age.[31]
• Renal Impairment: As Sulpiride is almost exclusively eliminated by the kidneys, dose reduction is mandatory in patients with renal insufficiency to prevent drug accumulation and toxicity. The following adjustments based on creatinine clearance (CrCl) are recommended [26]:
• CrCl 30-60 mL/min: Administer 2/3 of the standard dose.
• CrCl 10-30 mL/min: Administer 1/2 of the standard dose or double the dosing interval.
• CrCl < 10 mL/min: Administer 1/3 of the standard dose or triple the dosing interval.

Table 6: Dosing Regimens for Key Therapeutic Indications
Indication	Patient Population	Typical Daily Dose Range	Maximum Daily Dose
Schizophrenia (Negative Symptoms)	Adult	400-800 mg (in 2 divided doses)	800 mg
Schizophrenia (Positive Symptoms)	Adult	800-1600 mg (in 2 divided doses)	2400 mg
Depression / Anxiety	Adult	50-300 mg (in divided doses)	600 mg
Vertigo / GI Disorders	Adult	150-300 mg (in divided doses)	300 mg
Behavioral Disorders	Pediatric (>6 years)	3-5 mg/kg	As per specialist
Renal Impairment (CrCl < 10 mL/min)	Adult	1/3 of standard dose	As per specialist

Section 8: Regulatory Status and Global Availability

This section clarifies the complex and inconsistent regulatory landscape of Sulpiride, which has led to significant disparities in its availability and use across the globe.

8.1. Approval Status with Major Regulatory Agencies

Sulpiride lacks marketing authorization from the world's most influential centralized regulatory bodies.

• FDA (United States), Health Canada, and EMA (European Union): Sulpiride is not approved by the U.S. Food and Drug Administration, Health Canada, or the European Medicines Agency for centralized, pan-European marketing.[1] This absence of approval in major Western markets significantly limits its global reach and suggests that its historical data package may not meet the stringent, modern standards for efficacy and safety required by these agencies.

The lack of approval from these key regulators is highly consequential. Sulpiride was first developed in the 1960s, a time when clinical trial methodologies and regulatory requirements were substantially different from today's harmonized International Council for Harmonisation (ICH) standards. The absence of a centralized EMA or FDA approval implies that when the drug was likely reviewed, its legacy evidence base—composed of older, smaller, and potentially less rigorously designed studies—was deemed insufficient to establish a favorable risk-benefit profile according to contemporary guidelines. This situation creates a global therapeutic disparity, where a drug used as a standard treatment in some nations is completely unavailable in others, not because of new negative safety data, but because its historical evidence has not been updated to meet the demands of modern regulatory science.

8.2. Availability and Use in Europe and Other Regions

Despite the lack of a centralized EMA approval, Sulpiride is authorized for use in many individual countries through national regulatory processes.

• Europe: It is approved and widely used in several individual European countries.[1] An observational study on its use in somatoform disorders was conducted in Germany, Spain, France, Belgium, and Portugal, confirming its clinical use in these nations.[42] It is also available by prescription in Poland.[43] The related benzamide, amisulpride, is noted as being available in Belgium, the UK, and Germany, further highlighting the regional use of this drug class.[44]
• Other Regions: Sulpiride is commonly used in many parts of the world, including Asia, Central America, South Africa, and South America.[3] Its approval in Japan is particularly notable, as it is indicated for both schizophrenia and major depressive disorder, fully embracing its dual pharmacological action.[3]

8.3. Regulatory Standing in Australia

• Therapeutic Goods Administration (TGA): Sulpiride is not approved for therapeutic use in Australia and is not listed on the Australian Register of Therapeutic Goods (ARTG).[3]
• Australian Industrial Chemicals Introduction Scheme (AICIS): The compound is listed under its CAS number in the AICIS database.[2] It is critical to understand that AICIS regulates chemicals for industrial use (e.g., in manufacturing, cosmetics, cleaning products) and its inclusion does not in any way imply approval or safety for human therapeutic consumption.[46]
• Research Use: While not approved for general marketing, related compounds like "Sulpiride N-Oxide" are available from chemical suppliers in Australia for use in clinical trials and research settings, which can be conducted under specific TGA regulations for investigational products.[47]

Section 9: Synthesis and Concluding Expert Analysis

This final section synthesizes the preceding information into a cohesive expert analysis of Sulpiride's profile and its place in modern pharmacotherapy.

9.1. Summary of Sulpiride's Therapeutic Profile

Sulpiride is a pharmacologically unique agent whose clinical utility is a direct consequence of its dose-dependent bimodal action on the dopamine system. At low doses, it functions as a disinhibiting agent with antidepressant and anxiolytic properties, while at high doses, it acts as a potent antipsychotic. This allows it to treat a broad spectrum of disorders, from depression to the positive and negative symptoms of schizophrenia. Its high selectivity for D2/D3 receptors spares it from many of the autonomic, antihistaminic, and anticholinergic side effects that plague other antipsychotics. However, this selectivity does not protect it from the profound consequences of potent D2 blockade, resulting in a significant risk of extrapyramidal symptoms and hyperprolactinemia. Its pharmacokinetic profile is defined by poor oral bioavailability and an almost complete reliance on renal excretion, making it a high-risk agent in the elderly and in those with renal impairment.

9.2. Key Considerations for Clinical Practice

The safe and effective use of Sulpiride in the clinical setting demands a nuanced understanding of its properties.

• Dose is Paramount: The most critical aspect of prescribing Sulpiride is the selection of an appropriate dose for the intended effect. The vast difference between an antidepressant dose (e.g., 150 mg/day) and an antipsychotic dose (e.g., 1200 mg/day) means that dose selection is not merely a titration but a choice of pharmacological mechanism.
• Patient Selection and Monitoring: Careful patient selection is essential. It should be used with extreme caution, if at all, in patients with pre-existing Parkinson's disease, a history of arrhythmias, or risk factors for QTc prolongation. Baseline and periodic monitoring of renal function is crucial, especially in older adults. Clinicians must be vigilant for the emergence of EPS and should counsel patients on the endocrine side effects related to hyperprolactinemia.
• Administration for Consistency: To overcome the pharmacokinetic challenge of poor and variable absorption, patients should be counseled on administration relative to food. For the most consistent therapeutic effect, taking Sulpiride on an empty stomach is preferable. If this is not tolerated, it should be taken consistently with food to avoid day-to-day fluctuations in plasma levels.

9.3. Future Research Directions

The existing evidence base for Sulpiride, while extensive, has significant limitations that present clear opportunities for future research.

• Modernization of Clinical Evidence: There is a pressing need for large-scale, multicenter, randomized controlled trials that meet modern regulatory standards. Such trials are essential to definitively establish its risk-benefit profile, particularly in treatment-resistant schizophrenia, which could pave the way for broader regulatory approval and clarify its place alongside newer agents.
• Exploring Non-Dopaminergic Actions: The clinical relevance of Sulpiride's interactions with targets like carbonic anhydrases and cholinesterase is entirely unknown. Research into these mechanisms could uncover novel therapeutic applications or explain certain idiosyncratic side effects.
• Enantiomer-Specific Trials: Head-to-head clinical trials comparing racemic Sulpiride with its pure, active enantiomer, levosulpiride, are warranted. Such studies could determine whether levosulpiride offers an improved therapeutic index, with similar efficacy but a reduced side effect burden, which would represent a significant clinical advance.
• Cognitive and Motivational Effects: Preclinical research has revealed paradoxical effects of Sulpiride on learning and reward processing within the ventral pallidum.[48] Further investigation is needed to understand how these findings translate to human patients, particularly regarding the drug's impact on motivation, anhedonia, and cognitive function, which are core domains of impairment in schizophrenia and depression.

Works cited

1. [Sulpiride: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 20, 2025, ][https://go.drugbank.com/drugs/DB00391]
2. [Sulpiride | C15H23N3O4S | CID 5355 - PubChem, accessed October 20, 2025, ][https://pubchem.ncbi.nlm.nih.gov/compound/Sulpiride]
3. [Sulpiride - Wikipedia, accessed October 20, 2025, ][https://en.wikipedia.org/wiki/Sulpiride]
4. [(±)-Sulpiride 15676-16-1 - Sigma-Aldrich, accessed October 20, 2025, ][https://www.sigmaaldrich.com/US/en/product/sigma/s8010]
5. [CAS No : 15676-16-1 | Product Name : Sulpiride- API - Pharmaffiliates, accessed October 20, 2025, ][https://www.pharmaffiliates.com/en/15676\-16\-1\-sulpiride\-pa1935000\.html]
6. [sulpiride | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 20, 2025, ][https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab\=biology\&ligandId\=5501]
7. [15676-16-1 | CAS DataBase - ChemicalBook, accessed October 20, 2025, ][https://m.chemicalbook.com/CASEN\_15676\-16\-1\.htm]
8. [Sulpiride | 15676-16-1 - ChemicalBook, accessed October 20, 2025, ][https://www.chemicalbook.com/ChemicalProductProperty\_EN\_CB4141314\.htm]
9. [What is Sulpiride used for? - Patsnap Synapse, accessed October 20, 2025, ][https://synapse.patsnap.com/article/what\-is\-sulpiride\-used\-for]
10. [Sulpiride - MentalHealth.com, accessed October 20, 2025, ][https://www.mentalhealth.com/library/sulpiride\-uses\-dosage\-side\-effects]
11. [What is Dogmatil 50mg? - Vinmec, accessed October 20, 2025, ][https://www.vinmec.com/eng/blog/what\-is\-dogmatil\-50mg\-en]
12. [(R,S)-Sulpiride, D2-like dopamine receptor antagonist (CAS 15676-16-1) | Abcam, accessed October 20, 2025, ][https://www.abcam.com/en\-us/products/biochemicals/rs\-sulpiride\-d2\-like\-dopamine\-receptor\-antagonist\-ab120578]
13. [SULPIRIDE - precisionFDA, accessed October 20, 2025, ][https://precision.fda.gov/ginas/app/ui/substances/d7981da0\-4730\-4af3\-9890\-d0d7f42e2782]
14. [Levosulpiride - Wikipedia, accessed October 20, 2025, ][https://en.wikipedia.org/wiki/Levosulpiride]
15. [Sulpiride in the treatment of depression - A review on safety and efficacy - ResearchGate, accessed October 20, 2025, ][https://www.researchgate.net/publication/287325376\_Sulpiride\_in\_the\_treatment\_of\_depression\_\-\_A\_review\_on\_safety\_and\_efficacy]
16. [(±)-Sulpiride 15676-16-1 - Sigma-Aldrich, accessed October 20, 2025, ][https://www.sigmaaldrich.com/IN/en/product/sigma/s8010]
17. [What is the mechanism of Sulpiride? - Patsnap Synapse, accessed October 20, 2025, ][https://synapse.patsnap.com/article/what\-is\-the\-mechanism\-of\-sulpiride]
18. [A risk-benefit assessment of sulpiride in the treatment of schizophrenia, accessed October 20, 2025, ][https://pubmed.ncbi.nlm.nih.gov/8800626/]
19. [The mode of action of sulpiride as an atypical antidepressant agent. | DrugBank Online, accessed October 20, 2025, ][https://go.drugbank.com/articles/A229678]
20. [Detecting Potential Adverse Reactions of Sulpiride in Schizophrenic Patients by Prescription Sequence Symmetry Analysis | PLOS One - Research journals, accessed October 20, 2025, ][https://journals.plos.org/plosone/article?id\=10\.1371/journal.pone.0089795]
21. [Showing BioInteractions for Sulpiride (DB00391) | DrugBank Online, accessed October 20, 2025, ][https://go.drugbank.com/drugs/DB00391/biointeractions]
22. [Effects of food intake and meal size on the bioavailability of sulpiride in two dosage forms., accessed October 20, 2025, ][https://www.semanticscholar.org/paper/Effects\-of\-food\-intake\-and\-meal\-size\-on\-the\-of\-in\-Shinkuma\-Hamaguchi/96de19f2826554b8b6c50d491c3a5d41e05decec]
23. [Effects of food intake and meal size on the bioavailability of sulpiride ..., accessed October 20, 2025, ][https://pubmed.ncbi.nlm.nih.gov/2258254/]
24. [Sulpiride - Prescriber's Guide - Cambridge University Press, accessed October 20, 2025, ][https://www.cambridge.org/core/books/prescribers\-guide/sulpiride/C2D916E52E8FCFA8BAAEC2C13AC17636]
25. [[Toxicity of sulpiride]. | DrugBank Online, accessed October 20, 2025, ][https://go.drugbank.com/articles/A229588]
26. [Summary of Product Characteristics - HPRA, accessed October 20, 2025, ][https://assets.hpra.ie/products/Human/37307/Licence\_PA22992\-009\-001\_27092022115109\.pdf]
27. [The efficacy of sulpiride augmentation for schizophrenia | Cochrane, accessed October 20, 2025, ][https://www.cochrane.org/evidence/CD008125\_efficacy\-sulpiride\-augmentation\-schizophrenia]
28. [Sulpiride - NeuRA Library, accessed October 20, 2025, ][https://library.neura.edu.au/schizophrenia/treatments/physical/pharmaceutical/first\-generation\-antipsychotics/sulpiride/index.html]
29. [Sulpiride Terminated Phase 3 Trials for Depression / Schizophrenia / Dementia / Anxiety Disorders / Psychophysiological Disorders Treatment | DrugBank Online, accessed October 20, 2025, ][https://go.drugbank.com/drugs/DB00391/clinical\_trials?conditions\=DBCOND0027904%2CDBCOND0060453%2CDBCOND0018735%2CDBCOND0063832%2CDBCOND0018504\&phase\=3\&purpose\=treatment\&status\=terminated]
30. [SULPIRIDE 50 OETHMAAN Capsules - Equity Pharmaceuticals, accessed October 20, 2025, ][https://www.equitypharmaceuticals.co.za/downloads/PI%20Sulpiride%2050%20Oethmaan%20\_approved04012019\_for%20website.pdf]
31. [Uses of Sulpiride 50 mg - Vinmec, accessed October 20, 2025, ][https://www.vinmec.com/eng/blog/uses\-of\-sulpiride\-50mg\-en]
32. [Sulpiride - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed October 20, 2025, ][https://www.ncbi.nlm.nih.gov/books/NBK501450/]
33. [Risks of Sulpiride-Induced Parkinsonism in Peptic Ulcer ... - Frontiers, accessed October 20, 2025, ][https://www.frontiersin.org/journals/pharmacology/articles/10\.3389/fphar.2020\.00433/full]
34. [Controlled Trial of Sulpiride in Chronic Schizophrenic Patients | The British Journal of Psychiatry - Cambridge University Press & Assessment, accessed October 20, 2025, ][https://www.cambridge.org/core/journals/the\-british\-journal\-of\-psychiatry/article/controlled\-trial\-of\-sulpiride\-in\-chronic\-schizophrenic\-patients/6F82F886803FE1D5AD159EEAF5FC755C]
35. [Sulpiride Completed Phase 4 Trials for Schizoaffective Disorders / Schizophrenia Spectrum and Other Psychotic Disorders / Schizophrenia Treatment - DrugBank, accessed October 20, 2025, ][https://go.drugbank.com/drugs/DB00391/clinical\_trials?conditions\=DBCOND0033299%2CDBCOND0018504%2CDBCOND0081331\&phase\=4\&purpose\=treatment\&status\=completed]
36. [Study Details | NCT01615185 | A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia | ClinicalTrials.gov, accessed October 20, 2025, ][https://clinicaltrials.gov/study/NCT01615185]
37. [Sulpiride - HealthHub, accessed October 20, 2025, ][https://www.healthhub.sg/medication\-devices\-and\-treatment/medications/sulpiride]
38. [www.medicines.org.uk, accessed October 20, 2025, ][https://www.medicines.org.uk/emc/files/pil.13116\.pdf]
39. [Sulpiride (Dolmatil) - Antipsychotic - Patient.info, accessed October 20, 2025, ][https://patient.info/medicine/sulpiride\-2]
40. [SULPIRIDE Tablets 50mg "CH" [for central nervous system] | Kusuri-no-Shiori(Drug Information Sheet), accessed October 20, 2025, ][https://www.rad\-ar.or.jp/siori/english/search/result?n\=44007]
41. [SULPIRIDE Tablets 50mg "CH" [for gastrointestinal use] | Kusuri-no-Shiori(Drug Information Sheet), accessed October 20, 2025, ][https://www.rad\-ar.or.jp/siori/english/search/result?n\=44006]
42. [Sulpiride in the Treatment of Somatoform Disorders: Results of a European Observational Study to Characterize the Responder Profile - ResearchGate, accessed October 20, 2025, ][https://www.researchgate.net/publication/11676707\_Sulpiride\_in\_the\_Treatment\_of\_Somatoform\_Disorders\_Results\_of\_a\_European\_Observational\_Study\_to\_Characterize\_the\_Responder\_Profile]
43. [Can Sulpiride be bought in the UK? - GdziePoLek, accessed October 20, 2025, ][https://www.gdziepolek.pl/opinie\-i\-pytania/121520/kann\-man\-sulpiridi\-m\-ausland\-kaufen?lang\=en]
44. [[Amisulpride: a treatment option for psychotic disorders soon to be available in the Netherlands] - PubMed, accessed October 20, 2025, ][https://pubmed.ncbi.nlm.nih.gov/26552930/]
45. [Australian Register of Therapeutic Goods (ARTG), accessed October 20, 2025, ][https://www.tga.gov.au/products/australian\-register\-therapeutic\-goods\-artg]
46. [Australian Industrial Chemicals Introduction Scheme (AICIS) - PubChem Data Source, accessed October 20, 2025, ][https://pubchem.ncbi.nlm.nih.gov/source/26627]
47. [Shop | Novachem Reference Standards Australia, accessed October 20, 2025, ][https://novachem.com.au/shop/category/healthcare\-therapeutics\-5/page/15?attrib\=7\-25\&order\=name\+asc]
48. [The antipsychotic drug sulpiride in the ventral pallidum ..., accessed October 20, 2025, ][https://pmc.ncbi.nlm.nih.gov/articles/PMC9649625/]